- No posts yet.
- NCPE Assessment: Belzutifan not cost-effective for VHL disease-associated tumours at current price ncpe.ie | 87d ago
- NCPE Recommends Belzutifan (Welireg) Not Reimbursed for VHL Disease on Cost-Effectiveness Grounds ncpe.ie | 87d ago
- NCPE Recommends Against Reimbursement of Belzutifan (Welireg) for von Hippel-Lindau Disease in Ireland ncpe.ie | 63d ago
- Rapid Review of Rozanolixizumab (Rystiggo) for gMG Completed by NCPE ncpe.ie | 59d ago
- NCPE Rapid Review Recommends Full HTA for Zilucoplan (Zilbrysq) for Generalized Myasthenia Gravis ncpe.ie | 61d ago
- Dostarlimab (Jemperli) – NCPE Rapid Review Recommends Full HTA for Endometrial Cancer ncpe.ie | 67d ago
- National Centre for Pharmacoeconomics Publishes Budget Impact Guideline Version 1.1 ncpe.ie | 105d ago
- NCPE Ireland HTA for Opdualag (nivolumab+relatlimab) for advanced melanoma: status update ncpe.ie | 66d ago
- NCPE Publishes Updated Budget Impact Model Template v2.3 for Drug Reimbursement Submissions ncpe.ie | 105d ago
- NCPE Releases Full HTA Submission Template Version 3.1 for Pharmacoeconomic Assessments in Ireland ncpe.ie | 676d ago
Showing page 1 of 1
(11 total results)
← Prev
Next →